Skip to content

A clinical trial to examine the immunomodulatory effect of Triphala in Upper Respiratory Tract Illness in adults

A Randomized Placebo Controlled clinical trial to examine the immunomodulatory effect of Triphala in Recurrent Upper Respiratory Tract Illness in adults

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/045079
Enrollment
60
Registered
2022-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

None listed

Sponsors

CSIRCIMAP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. People between 18 -35 (Both included) year age 2. Of either gender 3. Suffering with recurrent episodes of upper respiratory tract illness ( 2 or more episodes in a year) 4. For more than one year are eligible to participate in the intervention study. 5. The eligibility is subject to the absence of known causes leading to recurrence of URT illness (smoking, occupational exposure of pollutants, persisting infection, immunosuppressive medication etc.) 6. Eligibility in the intervention group is further subject to informed consent duly obtained from the prospective participants.

Exclusion criteria

Exclusion criteria: 1.Lower respiratory tract illness including Pneumonia (either viral or bacterial), Bronchitis, Tuberculosis and Bronchiolitis will be excluded. 2.Conditions other than those mentioned in inclusion criteria will be excluded. 3.People not ready to stop taking health and nutritional supplements will not be recruited. 4.Those having a history of having ayurvedic treatment for any reason in past 4 weeks prior to the date of recruitment will not be included.

Design outcomes

Primary

MeasureTime frame
1.Plasma cytokine profile 2. NK cells activity 3.Monocytes 4. Dendritic cells 5.T cells, B cells Timepoint: Base line 2 weeks 4 weeks 6 weeks 10 weeks

Secondary

MeasureTime frame
drug safety assessment KFT LFTTimepoint: 6 weeks 10 weeks

Countries

India

Contacts

Public ContactSanjeev Rastogi

State Ayurvedic College and Hospital, Lucknow

rastogisanjeev@rediffmail.com9415022955

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026